Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025European PsychiatryOpen Access

Peripartum administration of esketamine: a way to prevent postpartum depression?

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMatthew MartinRSR. De Hita SantillanaMSM Silva

Discussion

Loading...

Member takes

Overview

Literature review shows esketamine reduces postpartum depression incidence in pregnant women, highlighting safety concerns.

Key Points

  • Esketamine use reduces postpartum depression risk by 48% in women post C/S.
  • Intravenous esketamine offers higher bioavailability compared to intranasal forms.
  • PPD prevalence is notably higher in underdeveloped countries, requiring timely intervention.
  • Immediate adverse events from esketamine during surgery occur in 97.7% of patients.

Cite This Study

Martin et al. (2025) studied this question.

synapsesocial.com/papers/68d454cb31b076d99fa5a47ahttps://doi.org/10.1192/j.eurpsy.2025.2402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Perioperative use of esketamine for the prevention of postpartum depression after cesarean section: a meta-analysis2025 · 5 citations
  2. 2Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery2024 · 66 citations
  3. 3Ketamine and Esketamine for the Prevention of Postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesis2026
  4. 4Comment on: prophylactic esketamine to reduce postpartum depression in primiparae2026
  5. 5Reply to: prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial2026